company background image
DTIL

Precision BioSciences NasdaqGS:DTIL Stock Report

Last Price

US$1.34

Market Cap

US$148.7m

7D

-4.3%

1Y

-83.6%

Updated

04 Dec, 2022

Data

Company Financials +
DTIL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

DTIL Stock Overview

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States.

Precision BioSciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Precision BioSciences
Historical stock prices
Current Share PriceUS$1.34
52 Week HighUS$9.41
52 Week LowUS$1.11
Beta1.49
1 Month Change-4.29%
3 Month Change-14.65%
1 Year Change-83.64%
3 Year Change-93.18%
5 Year Changen/a
Change since IPO-92.32%

Recent News & Updates

Recent updates

Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Apr 19
Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)

Mar 21
Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)

Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely

Dec 31
Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely

Is Precision BioSciences (NASDAQ:DTIL) A Risky Investment?

Sep 24
Is Precision BioSciences (NASDAQ:DTIL) A Risky Investment?

Analysts Are Betting On Precision BioSciences, Inc. (NASDAQ:DTIL) With A Big Upgrade This Week

Jun 08
Analysts Are Betting On Precision BioSciences, Inc. (NASDAQ:DTIL) With A Big Upgrade This Week

New Forecasts: Here's What Analysts Think The Future Holds For Precision BioSciences, Inc. (NASDAQ:DTIL)

May 20
New Forecasts: Here's What Analysts Think The Future Holds For Precision BioSciences, Inc. (NASDAQ:DTIL)

Analysts Just Made A Major Revision To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Revenue Forecasts

Mar 23
Analysts Just Made A Major Revision To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Revenue Forecasts

Could The Precision BioSciences, Inc. (NASDAQ:DTIL) Ownership Structure Tell Us Something Useful?

Feb 26
Could The Precision BioSciences, Inc. (NASDAQ:DTIL) Ownership Structure Tell Us Something Useful?

A Look At Precision BioSciences' (NASDAQ:DTIL) Share Price Returns

Jan 04
A Look At Precision BioSciences' (NASDAQ:DTIL) Share Price Returns

Shareholder Returns

DTILUS BiotechsUS Market
7D-4.3%4.2%1.5%
1Y-83.6%-7.4%-14.9%

Return vs Industry: DTIL underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: DTIL underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is DTIL's price volatile compared to industry and market?
DTIL volatility
DTIL Average Weekly Movement8.9%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: DTIL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: DTIL's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006194Michael Amorosohttps://www.precisionbiosciences.com

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.

Precision BioSciences, Inc. Fundamentals Summary

How do Precision BioSciences's earnings and revenue compare to its market cap?
DTIL fundamental statistics
Market CapUS$148.68m
Earnings (TTM)-US$105.44m
Revenue (TTM)US$20.84m

7.1x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DTIL income statement (TTM)
RevenueUS$20.84m
Cost of RevenueUS$0
Gross ProfitUS$20.84m
Other ExpensesUS$126.28m
Earnings-US$105.44m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.95
Gross Margin100.00%
Net Profit Margin-505.97%
Debt/Equity Ratio26.3%

How did DTIL perform over the long term?

See historical performance and comparison